Get started
Mersana Therapeutics, Inc.Mersana Therapeutics, Inc.Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

MRSN chart


Full chart

MRSN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪47.83 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.5652 USD
Net income (FY)
‪−69.19 M‬ USD
Revenue (FY)
‪40.50 M‬ USD
Shares float
‪85.81 M‬
Beta (1Y)
2.96

Employees


Employees (FY)
102
Change (1Y)
−21 −17.07%
Revenue / Employee (1Y)
‪397.03 K‬ USD
Net income / Employee (1Y)
‪−678.35 K‬ USD

About Mersana Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Martin H. Huber
Website
mersana.com
Headquarters
Cambridge
Founded
2001
FIGI
BBG001CPSVF3
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

MRSN news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as MRSN.

Frequently Asked Questions


The current price of MRSN is 0.3615 USD — it has increased by 5.47% in the past 24 hours. Watch Mersana Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Mersana Therapeutics, Inc. stocks are traded under the ticker MRSN.
MRSN stock has risen by 11.90% compared to the previous week, the month change is a 2.35% rise, over the last year Mersana Therapeutics, Inc. has showed a −87.70% decrease.
We've gathered analysts' opinions on Mersana Therapeutics, Inc. future price: according to them, MRSN price has a max estimate of 9.00 USD and a min estimate of 1.00 USD. Watch MRSN chart and read a more detailed Mersana Therapeutics, Inc. stock forecast: see what analysts think of Mersana Therapeutics, Inc. and suggest that you do with its stocks.
MRSN reached its all-time high on Dec 29, 2020 with the price of 29.0900 USD, and its all-time low was 0.2589 USD and was reached on Apr 10, 2025. View more price dynamics on MRSN chart.
See other stocks reaching their highest and lowest prices.
MRSN stock is 10.57% volatile and has beta coefficient of 2.96. Track Mersana Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Mersana Therapeutics, Inc. there?
Today Mersana Therapeutics, Inc. has the market capitalization of ‪47.83 M‬, it has increased by 2.07% over the last week.
Yes, you can track Mersana Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Mersana Therapeutics, Inc. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
MRSN earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.16 USD resulting in a 31.30% surprise. The estimated earnings for the next quarter are −0.19 USD per share. See more details about Mersana Therapeutics, Inc. earnings.
Mersana Therapeutics, Inc. revenue for the last quarter amounts to ‪16.36 M‬ USD, despite the estimated figure of ‪6.91 M‬ USD. In the next quarter, revenue is expected to reach ‪6.05 M‬ USD.
MRSN net income for the last quarter is ‪−14.12 M‬ USD, while the quarter before that showed ‪−11.50 M‬ USD of net income which accounts for −22.75% change. Track more Mersana Therapeutics, Inc. financial stats to get the full picture.
No, MRSN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 29, 2025, the company has 102 employees. See our rating of the largest employees — is Mersana Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Mersana Therapeutics, Inc. EBITDA is ‪−71.71 M‬ USD, and current EBITDA margin is −177.07%. See more stats in Mersana Therapeutics, Inc. financial statements.
Like other stocks, MRSN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Mersana Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Mersana Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Mersana Therapeutics, Inc. stock shows the sell signal. See more of Mersana Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.